Back to top
more

AC Immune (ACIU)

(Real Time Quote from BATS)

$3.16 USD

3.16
77,395

-0.04 (-1.25%)

Updated Nov 11, 2024 01:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -159.52% and 99.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)

by Zacks Equity Research

Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune

by Zacks Equity Research

Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.

Kinjel Shah headshot

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab

by Kinjel Shah

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

by Zacks Equity Research

Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.

Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod

by Zacks Equity Research

The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.

Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does AC Immune (ACIU) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sweta Killa headshot

5 Small-Cap Stocks to Play the January Effect

by Sweta Killa

Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.

AC Immune (ACIU) Upgraded to Buy: Here's Why

by Zacks Equity Research

AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

by Zacks Equity Research

Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.

Ekta Bagri headshot

Alzheimer's Disease Space Evolves in 2023: Stocks in Focus

by Ekta Bagri

The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.

Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

by Zacks Equity Research

Here is how Aquestive Therapeutics (AQST) and AC Immune (ACIU) have performed compared to their sector so far this year.

Are Medical Stocks Lagging AC Immune (ACIU) This Year?

by Zacks Equity Research

Here is how AC Immune (ACIU) and Exact Sciences (EXAS) have performed compared to their sector so far this year.

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

NeoGenomics (NEO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

by Zacks Equity Research

AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

by Zacks Equity Research

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen

by Kinjel Shah

Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.